Application of IL-2 and other cytokines in renal cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.4.4.455PMID 15102596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic Antitumor Effects of Combination Immunotherapy with Recombinant Interleukin-2 and a Recombinant Hybrid a-Interferon in the Treatment of Established Murine Hepatic MÃ © tastases

  2006cited by this paper
• Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.

  2003cited by this paper
• Cancer Statistics, 2003

  2003cited by this paper
• Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.

  2003cited by this paper
• Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

  2003cited by this paper
• Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

  2003cited by this paper
• Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

  2003cited by this paper
• Renal cell carcinoma with retroperitoneal lymph nodes

  2003cited by this paper
• Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.

  2003cited by this paper
• Lymphocyte Counts Independently Predict Overall Survival in Advanced Cancer Patients: A Biomarker for IL-2 Immunotherapy

  2003cited by this paper
• Immune Effects of Escalating Doses of Granulocyte-Macrophage Colony-Stimulating Factor Added to a Fixed, Low-Dose, Inpatient Interleukin-2 Regimen: A Randomized Phase I Trial in Patients With Metastatic Melanoma and Renal Cell Carcinoma

  2003cited by this paper
• Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

  2003cited by this paper
• Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

  2003cited by this paper
• Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.

  2002cited by this paper
• Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil.

  2002cited by this paper
• Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma

  2002cited by this paper
• Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.

  2002cited by this paper
• Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.

  2002cited by this paper
• A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.

  2002cited by this paper
• Immunotherapy of metastatic renal cell cancer.

  2002cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial

  2002cited by this paper
• Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.

  2002cited by this paper
• Advances in Allogeneic Stem Cell Transplantation: Directing Graft‐Versus‐Leukemia at Solid Tumors

  2002cited by this paper
• Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation

  2001cited by this paper
• Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

  2001cited by this paper
• Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

  2001cited by this paper
• Vaccine and gene therapy of renal cell carcinoma.

  2001cited by this paper
• Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

  2000cited by this paper
• Granulocyte‐macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma

  2000cited by this paper
• Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

  2000cited by this paper
• Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study

  2000cited by this paper
• Treatment of Metastatic Renal Cell Carcinoma With Activated Autologous Macrophages and Granulocyte–Macrophage Colony-Stimulating Factor

  2000cited by this paper
• Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

  2000cited by this paper
• A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.

  2000cited by this paper
• Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

  1999cited by this paper
• Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

  1999cited by this paper
• Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

  1999cited by this paper
• Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

  1999cited by this paper
• Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

  1998cited by this paper
• Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

  1998cited by this paper
• Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

  1998cited by this paper
• Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

  1998cited by this paper
• Granulocyte‐macrophage‐colony stimulating factor in metastatic renal cell carcinoma

  1998cited by this paper
• Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

  1997cited by this paper
• Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.

  1997cited by this paper
• Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.

  1997cited by this paper
• Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

  1997cited by this paper
• Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

  1997cited by this paper
• Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.

  1997cited by this paper
• Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.

  1997cited by this paper
• Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

  1997cited by this paper
• Immunotherapy of metastatic renal cell cancer.

  1996cited by this paper
• Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma.

  1996cited by this paper
• Phase II trial of subcutaneously administered granulocyte‐macrophage colony‐stimulating factor in patients with metastatic renal cell carcinoma

  1996cited by this paper
• Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.

  1996cited by this paper
• Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.

  1996cited by this paper
• Renal-cell carcinoma.

  1996cited by this paper
• Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

  1996cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.

  1995cited by this paper
• Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.

  1995cited by this paper
• Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

  1994cited by this paper
• Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.

  1994cited by this paper
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

  1994cited by this paper
• Phase I Study of Interleukin-2 Combined with Interferon-α and 5-Fluorouracil in Patients with Metastatic Renal Cell Cancer

  1994cited by this paper
• Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.

  1994cited by this paper
• Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.

  1993cited by this paper
• Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.

  1993cited by this paper
• Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

  1993cited by this paper
• Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors

  1993cited by this paper
• Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.

  1993cited by this paper
• Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.

  1993cited by this paper
• Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

  1993cited by this paper
• Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

  1993cited by this paper
• A Comparison of 2 Modes of Administration of Recombinant Interleukin-2: Continuous Intravenous Infusion Alone Versus Subcutaneous Administration plus Interferon Alpha in Patients with Advanced Renal Cell Carcinoma.

  1993cited by this paper
• Daily alternating administration of high‐dose alpha‐2b‐interferon and interleukin‐2 bolus infusion in metastatic renal cell cancer. A phase II study

  1993cited by this paper
• Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma

  1993cited by this paper
• Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.

  1992cited by this paper
• Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.

  1992cited by this paper
• Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.

  1992cited by this paper
• Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.

  1992cited by this paper
• Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy.

  1992cited by this paper
• Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

  1992cited by this paper
• A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

  1992cited by this paper
• Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.

  1991cited by this paper
• Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.

  1991cited by this paper
• Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects [see comments]

  1990cited by this paper
• A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

  1990cited by this paper
• Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

  1989cited by this paper
• Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

  1989cited by this paper
• Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma.

  1989cited by this paper
• Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

  1988cited by this paper
• Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

  1988cited by this paper
• IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells.

  1988cited by this paper
• Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

  1988cited by this paper

• Immunotherapy in Renal Cell Carcinoma.

  2025cites this paper
• SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy

  2025cites this paper
• HIF Regulates Multiple Translated Endogenous Retroviruses: Implications for Cancer Immunotherapy

  2025cites this paper
• Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases

  2023cites this paper
• Interleukin-2 and Oncolytic virotherapy: A new perspective in cancer therapy.

  2023cites this paper
• Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

  2023cites this paper
• Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer

  2022cites this paper
• Molecular and cellular factors determining the functional pleiotropy of cytokines

  2022cites this paper
• Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management

  2022cites this paper
• Competitive inhibition of IL-2/IL-2R has a dual effect on HSC ex vivo expansion and IL-2R (CD25) content.

  2022cites this paper
• The potential for Treg-enhancing therapies in transplantation

  2022cites this paper
• Emerging principles of cytokine pharmacology and therapeutics

  2022cites this paper
• Cytochalasin B-Induced Membrane Vesicles from Human Mesenchymal Stem Cells Overexpressing IL2 Are Able to Stimulate CD8+ T-Killers to Kill Human Triple Negative Breast Cancer Cells

  2021cites this paper
• ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

  2020cites this paper
• Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

  2020cites this paper
• Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro

  2020cites this paper
• Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment

  2020cites this paper
• Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential.

  2019cites this paper
• Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.

  2019cites this paper
• Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases

  2019cites this paper
• NK1.1 receptor ligation or tumour interactions prime NK cells for IL2-mediated metabolic and functional responses

  2019cites this paper
• Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review

  2018cites this paper
• Retraction: Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma

  2018cites this paper
• Biology of IL‐2 and its therapeutic modulation: Mechanisms and strategies

  2018cites this paper
• 4-18-2017 The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31 st anniversary annual meeting Howard

  2018cites this paper
• Reprogramming immune proteins as therapeutics using molecular engineering

  2018cites this paper
• Nanotechnology Enters the Renal Cancer Drug Delivery Arena: A Review

  2018cites this paper
• Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy

  2018cites this paper
• A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2

  2018cites this paper
• The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting

  2017cites this paper
• Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy

  2016cites this paper
• Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect

  2016cites this paper
• Novel IL-2-Poly(HPMA)Nanoconjugate Based Immunotherapy.

  2015cites this paper
• Development of Combination Therapy with Targeted Agents

  2015cites this paper
• Insights into cytokine-receptor interactions from cytokine engineering.

  2015cites this paper
• Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

  2015cites this paper
• Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model

  2015cites this paper
• Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.

  2014cites this paper
• Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer.

  2014cites this paper
• Immunologic Therapy of Renal Cell Carcinoma

  2014cites this paper
• Neutrophil activation induces peripheral immunosuppression in glioblastoma and stroke

  2013cites this paper
• Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

  2013cites this paper
• Expression, Identification and Characterize of CD25-Binding Epitope Modified Human IL-2 in Pichia pastoris

  2013influential citation
• T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

  2013cites this paper
• The role of interleukin-2 during homeostasis and activation of the immune system

  2012cites this paper
• Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance.

  2012cites this paper
• Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype.

  2011cites this paper
• Immunomodulatory cytokines as therapeutic agents for melanoma.

  2011cites this paper
• Diagnosis and treatment of gastric metastasis of clear cell renal cell carcinoma: a case report and review of literatures: Diagnosis and treatment of gastric metastasis of clear cell renal cell carcinoma: a case report and review of literatures

  2011cites this paper
• Combined Immunochemotherapy in Selected Patients With Metastatic Renal Cell Carcinoma: HLA Class II Genotype Can Help to Predict Response to Therapy

  2011cites this paper
• Correction for “ Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

  2011influential citation
• Economic Burden of Renal Cell Carcinoma

  2011cites this paper
• Cancer immunotherapy comes of age

  2011cites this paper
• Cancer immunotherapy comes of age.

  2011cites this paper
• Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

  2010influential citation
• Progress in the Management of Advanced Renal Cell Carcinoma (RCC)

  2010cites this paper
• Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention.

  2010cites this paper
• Using poly-N-acetyl glucosamine gel matrix to deliver IL-12 with anti-schistosomasis vaccination.

  2010cites this paper
• A survey of therapy for advanced renal cell carcinoma.

  2010cites this paper
• [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].

  2009cites this paper
• Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

  2009cites this paper
• Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix

  2009cites this paper
• Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

  2009cites this paper
• Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

  2009cites this paper
• Medikamentöse Therapie des metastasierten Nierenzellkarzinoms: Eine Standortbestimmung nach Einführung der Multi-Tyrosinkinaseinhibitoren in Deutschland

  2009cites this paper
• Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biological and Clinical Studies

  2009cites this paper
• Interferon-&agr; in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial

  2008cites this paper
• Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.

  2008cites this paper
• Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.

  2008cites this paper
• Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience

  2008cites this paper
• Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.

  2008cites this paper
• Current immunotherapeutic strategies in renal cell carcinoma.

  2007cites this paper
• Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents

  2007cites this paper
• Evolving role of novel targeted agents in renal cell carcinoma.

  2007cites this paper
• Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393.

  2007cites this paper
• Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.

  2007cites this paper
• Renal Cell Cancer

  2007cites this paper
• Clinical aspects of indoleamine 2,3-dioxygenase (IDO)-initiated tryptophan metabolism: IDO is a target of drug discovery for various diseases

  2007cites this paper
• Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2

  2007cites this paper
• Targeted Therapy for Renal Cell Carcinoma: A New Treatment Paradigm

  2007cites this paper
• Integrated non‐invasive system for quantifying secreted human therapeutic hIL2

  2006cites this paper
• Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy

  2006cites this paper
• Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma.

  2006cites this paper
• Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions

  2006cites this paper
• Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease

  2006cites this paper
• Improved periplasmic production of biologically active murine interleukin-2 in Escherichia coli through a single amino acid change at the cleavage site

  2006cites this paper
• A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.

  2006cites this paper
• Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.

  2006cites this paper
• [Therapy strategies for advanced renal cell carcinoma].

  2006cites this paper
• Unusual gastric and pancreatic metastatic renal cell carcinoma presentation 10 years after surgery and immunotherapy: A case report and a review of literature.

  2006cites this paper
• Management of advanced renal cancer.

  2005cites this paper
• Interleukin-2 family cytokines: potential for therapeutic immmunoregulation

  2005influential citation
• Therapiestrategien des fortgeschrittenen Nierenkarzinoms

  2005cites this paper
• The design of a liver-selective form of interleukin-10 : a new strategy for the treatment of liver fibrosis.

  2005cites this paper
• Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

  2005cites this paper
• Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.

  2005cites this paper
• Advancing Cancer Biotherapy with Proteomics

  2005cites this paper
• Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

  2005cites this paper
• A Phase 2 Study of Moderate Dose Interleukin-2 and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic or Unresectable Renal Cell Carcinoma

  2005cites this paper
• Emerging drugs for renal cell carcinoma

  2005cites this paper